论文部分内容阅读
目的:研究IGFBP-3抗原在非小细胞肺癌(NSCLC)中的表达及其意义。方法:应用免疫组化技术对60例NSCLC肿瘤组织及其周围正常肺组织中IGFBP-3抗原表达进行检测和分析。结果:IGFBP-3在良性肺组织中表达定位于细胞质,而在肺癌组织中表达定位于细胞质和细胞核(分别称为IGFBP-3质表达和核表达),后二者的表达率分别为96.67%(58/60)和71.67%(43/60),IGFBP-3质表达在肺癌和良性肺组织间差异无统计学意义。在伴有淋巴结转移肺癌组织中IGFBP-3核表达显著低于无淋巴结转移肺癌组织,在低分化肺癌组织中IGFBP-3核表达显著低于中或高分化肺癌。结论:在NSCLC组织中,IGFBP-3核表达则可能与抑制肿瘤生长有关,对于判断NSCLC患者预后具有重要意义。
Objective: To study the expression of IGFBP-3 antigen in non-small cell lung cancer (NSCLC) and its significance. Methods: Immunohistochemical technique was used to detect and analyze the expression of IGFBP-3 antigen in 60 NSCLC tissues and their surrounding normal lung tissues. Results: The expression of IGFBP-3 localized in cytoplasm in benign lung tissues and localized in the cytoplasm and nucleus of lung cancer (respectively, IGFBP-3 expression and nuclear expression), the expression rates of the two were 96.67% (58/60) and 71.67% (43/60) respectively. There was no significant difference in the expression of IGFBP-3 between lung cancer and benign lung tissues. The nuclear expression of IGFBP-3 in lung cancer with lymph node metastasis was significantly lower than that without lymph node metastasis, and the expression of IGFBP-3 in poorly differentiated lung cancer was significantly lower than that in moderate or well-differentiated lung cancer. CONCLUSIONS: The expression of IGFBP-3 in NSCLC tissues may be related to the inhibition of tumor growth, which is of great significance for judging the prognosis of patients with NSCLC.